<DOC>
	<DOC>NCT00764946</DOC>
	<brief_summary>A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.</brief_summary>
	<brief_title>A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient is HIV positive Patient agrees to use (or have their partner use) birth control as defined by the study doctor If female, pregnant or breastfeeding Patient has used an investigational agent in the last 30 days Patient has acute hepatitis Patient has received MK0518 (raltegravir) before Patient has used another experimental HIVintegrase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>